Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Cellectar Biosciences, Inc. (CLRB : NSDQ)

• Company Description    Cellectar Biosciences, Inc. is developing agents to detect, treat and monitor a broad spectrum of cancers. It uses a novel phospholipid ether platform technology as a targeted delivery and retention vehicle. Cellectar Biosciences Inc., formerly known as Novelos Therapeutics, Inc., is headquartered in Madison, Wisconsin. Number of Employees: 11

• Price / Volume Information    Yesterday's Closing Price: $3.20 Daily Weekly Monthly 20 Day Moving Average: 3,033,820 shares Shares Outstanding: 7.99 (millions) Market Capitalization: $25.57 (millions) Beta: 0.43 52 Week High: $13.95 52 Week Low: $2.43 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 14.90% 9.29% 12 Week -8.83% -15.72% Year To Date 8.47% -1.20%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 100 CAMPUS DRIVE - FLORHAM PARK,NJ 07932 USA ph: 608-441-8120 fax: 608-441-8121 tjenkins@candeltx.com http://www.cellectar.com

• General Corporate Information    Officers JamesV.Caruso - ChiefExecutiveOfficer and Director Chad J. Kolean - ChiefFinancialOfficer Frederick W. Driscoll - Director Asher Alban Chanan-Khan - Director Stefan D. Loren - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED PRODUCTS Sector: Medical CUSIP: 15117F880 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/13/26 Share - Related Items Shares Outstanding: 7.99 Most Recent Split Date: 6.00 (0.03:1) Beta: 0.43 Market Capitalization: $25.57 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.47 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.34 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 9.09 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 65.93% vs. Previous Quarter: -150.94% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -349.24 12/31/25 - -298.05 09/30/25 - -214.33 ROA 03/31/26 - -153.18 12/31/25 - -144.59 09/30/25 - -106.02 Current Ratio 03/31/26 - 1.90 12/31/25 - 2.96 09/30/25 - 2.77 Quick Ratio 03/31/26 - 1.90 12/31/25 - 2.96 09/30/25 - 2.77 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 0.35 12/31/25 - 1.89 09/30/25 - 2.34 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.04 Debt-to-Capital 03/31/26 - 29.30 12/31/25 - 13.93 09/30/25 - 17.68

Powered by Zacks Investment Research ©